What changed
2026-07-26 14:34 UTC → 2026-07-27 19:06 UTC ·
added
removed
In late Late June 2026 the FDA announced a two‑day advisory meeting to reassess injectable synthetic peptides. The On 22 July the Pharmacy Compounding Advisory Committee met on 22 July and, despite an internal scientific review urging caution, added four peptides—BPC‑157, BPC‑157, KPV, TB‑500 and MOTS‑C—to MOTS‑C to the Category 1 bulk‑drug list. On 23 July The next day the panel voted 8‑6 (one abstention) to recommend seven unapproved injectable peptides—BPC‑157, TB‑500, KPV, MOTS‑C, DSIP, Semax and Epitalon—be placed on peptides for the Section 503A Bulk Drug Substances List, a move framed by members as supporting “medical freedom” and public benefit. Health Secretary Robert F. Kennedy Jr. promoted the market and has ties to several advisers. Two days later, on List. On 25 July, July the committee narrowly approved six of those seven compounds for inclusion. Approved indications include inclusion, endorsing BPC‑157 for ulcerative colitis, MOTS‑C for obesity and osteoporosis, and KPV and TB‑500 for wound healing; semax and epitalon also cleared, while emideltide was rejected failed by a single vote. Reported vote margins were 8‑6 for insomnia some compounds and narcolepsy. Agency scientists again warned 7‑5 for others. Members, largely appointed by Health Secretary Robert F. Kennedy Jr., included doctors and pharmacists with disclosed financial ties to the peptide industry. FDA staff reiterated that none of the peptides have robust human scientific evidence does not meet safety or and efficacy data, raising concerns about standards and warned of quality‑control, adverse‑event reporting, and the precedent of allowing untested compounds into the regulated pharmacy supply chain. concerns. The FDA will issue recommendation is non‑binding; a final FDA decision and open will follow a public comment period. period amid rising pressure from wellness‑influencer and biohacking communities.